Table 1.
CC | Total no. | Patient sex (%) |
Age (years) (%) |
Onset (%) |
Non-susceptibility (%) |
β-Lactamase (%) |
||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
N/R | female | male | N/R | 0–19 | 20–49 | 50–69 | 70+ | N/R | ≤48 h | >48 h | AMX | AMC | TZP | CTXa | CAZ | CIP | GEN | TGCa | IPM | CTX-M otherb | CTX-M-1 | CTX-M-9 | ESBL, non-CTX-M | non-ESBL | ||
73 | 449 | 0.2 | 59.5 | 40.3 | 0.0 | 3.6 | 12.5 | 20.7 | 63.3 | 1.3 | 64.4 | 34.3 | 55.9 | 27.8 | 9.1 | 1.5 | 1.8 | 1.3 | 1.6 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 1.1 | 98.9 |
131 | 302 | 0.3 | 42.7 | 57.0 | 0.7 | 3.0 | 6.6 | 25.8 | 63.9 | 0.0 | 50.0 | 50.0 | 83.4 | 59.3 | 22.2 | 35.0 | 29.5 | 64.2 | 20.2 | 0.0 | 0.0 | 0.3 | 32.5 | 0.3 | 1.0 | 65.9 |
95 | 245 | 0.0 | 63.7 | 36.3 | 0.4 | 9.4 | 13.5 | 23.7 | 53.1 | 0.8 | 64.5 | 34.7 | 45.3 | 13.9 | 2.9 | 0.0 | 0.0 | 0.4 | 2.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 100 |
69 | 149 | 0.0 | 72.5 | 27.5 | 0.0 | 2.7 | 18.1 | 23.5 | 55.7 | 0.7 | 65.8 | 33.6 | 81.9 | 32.2 | 10.1 | 1.4 | 2.0 | 6.7 | 4.0 | 0.7 | 0.0 | 0.0 | 0.7 | 0.0 | 0.0 | 99.3 |
12 | 119 | 0.0 | 49.6 | 50.4 | 0.8 | 3.4 | 11.8 | 22.7 | 61.3 | 0.0 | 68.9 | 31.1 | 71.4 | 28.6 | 7.6 | 1.8 | 5.0 | 0.8 | 3.4 | 0.0 | 0.0 | 0.0 | 0.8 | 0.0 | 1.7 | 97.5 |
Otherc | 902 | 0.2 | 50.4 | 49.3 | 0.4 | 4.5 | 11.2 | 27.3 | 56.5 | 1.1 | 57.0 | 41.9 | 60.9 | 27.7 | 9.3 | 5.3 | 5.3 | 15.2 | 6.4 | 0.1 | 0.2 | 0.2 | 2.2 | 0.1 | 1.0 | 96.5 |
Total | 2166 | 0.2 | 54.2 | 45.6 | 0.4 | 4.5 | 11.6 | 24.8 | 58.8 | 0.9 | 59.6 | 39.5 | 63.3 | 30.9 | 10.3 | 7.9 | 7.1 | 16.1 | 6.6 | 0.1 | 0.1 | 0.1 | 5.5 | 0.1 | 0.9 | 93.4 |
Onset ≤48 h considered as community onset and onset >48 h considered as hospital onset.
Values shaded grey are significantly different (P ≤ 0.0001) compared with the baseline CC73 group.
Values in bold are significant (P ≤ 0.05) compared with the baseline CC73 group.
N/R, not reported; AMX, amoxicillin; AMC, amoxicillin/clavulanate; TZP, piperacillin/tazobactam; CTX, cefotaxime; CAZ, ceftazidime; CIP, ciprofloxacin; GEN, gentamicin; TGC, tigecycline; IPM, imipenem.
aCefotaxime and tigecycline were tested in 2002–10 only.
b‘CTX-M other’ indicates an unidentified CTX-M group.
c‘Other’ CCs includes 902 isolates representing 443 STs, with no more than 65 isolates belonging to any CC.